Results 191 to 200 of about 2,078,021 (401)

Nicotinamide N‐methyltransferase promotes drug resistance in lung cancer, as revealed by nascent proteomic profiling

Molecular Oncology, EarlyView.
AZD9291 has shown promise in targeted cancer therapy but is limited by resistance. In this study, we employed metabolic labeling and LC–MS/MS to profile time‐resolved nascent protein perturbations, allowing dynamic tracking of drug‐responsive proteins. We demonstrated that increased NNMT expression is associated with drug resistance, highlighting NNMT ...
Zhanwu Hou, Zhen Wang, Fei Yang, Xiao Han, Lei Li, Huadong Liu   +5 more
wiley   +1 more source

Cardiotoxicity Induced by Protein Kinase Inhibitors in Patients with Cancer. [PDF]

Int J Mol Sci, 2022
Grela-Wojewoda A, Pacholczak-Madej R, Adamczyk A, Korman M, Püsküllüoğlu M.   +4 more
europepmc   +1 more source

UCN-01 and UCN-02, new selective inhibitors of protein kinase C. II. Purification, physico-chemical properties, structural determination and biological activities.

, 1989
ISAMI TAKAHASHI, Yutaka Saitoh, Mayumi Yoshida, Hiroshi Sano, Hirofumi Nakano, Makoto Morimoto, Tatsuya Tamaoki   +6 more
openalex   +2 more sources

Adenosine‐to‐inosine editing of miR‐200b‐3p is associated with the progression of high‐grade serous ovarian cancer

Molecular Oncology, EarlyView.
A‐to‐I editing of miRNAs, particularly miR‐200b‐3p, contributes to HGSOC progression by enhancing cancer cell proliferation, migration and 3D growth. The edited form is linked to poorer patient survival and the identification of novel molecular targets.
Magdalena Niemira, Anna Skwarska, Karolina Chwialkowska, Agnieszka Ostrowska, Gabriela Sokolowska, Anna Zeller, Anna Erol, Andrzej Eljaszewicz, Bartosz Hanczaruk, Anna Michalska‐Falkowska, Agnieszka Tarasik, Joanna Reszec‐Gielazyn, Pawel Knapp, Marcin Moniuszko, Adam Kretowski   +14 more
wiley   +1 more source

Retraction Note: Identification of protein kinase inhibitors to reprogram breast cancer cells. [PDF]

Cell Death Dis, 2022
Yuan J, Zhang F, You M, Yang Q.
europepmc   +1 more source

N-(2-Aminoethyl)-5-isoquinolinesulfonamide, a newly synthesized protein kinase inhibitor, functions as a ligand in affinity chromatography. Purification of Ca2+-activated, phospholipid-dependent and other protein kinases.

, 1985
Masaki Inagaki, Masato Watanabe, Hisashi Hidaka   +2 more
openalex   +1 more source

Differential inhibition of T cell receptor signal transduction and early activation events by a selective inhibitor of protein-tyrosine kinase. [PDF]

, 1990
James M. Trevillyan, Lu Yin, D. Atluru, C.A. Phillips, J M Bjorndahl   +4 more
openalex   +1 more source

The specificities of protein kinase inhibitors: an update.

Biochemical Journal, 2003
J. Bain, H. Mclauchlan, M. Elliott, P. Cohen   +3 more
semanticscholar   +1 more source

The influence of ROS1 fusion partners and resistance mechanisms in ROS1‐TKI‐treated non‐small cell lung cancer patients

Molecular Oncology, EarlyView.
This real‐world study of ROS1+ NSCLC highlights fusion diversity, treatment outcomes with crizotinib and lorlatinib, and in vitro experiments with resistance mechanisms. G2032R drives strong resistance to ROS1‐targeted TKIs, especially lorlatinib. Fusion partner location does not affect overall survival to crizotinib or lorlatinib. Findings support the
Fenneke Zwierenga, Christa Dijkhuizen, Patrick Korthuis, Wim Timens, Harry Groen, Jeroen Hiltermann, Anke van den Berg, Lyndsay Drayer, Anthonie van der Wekken   +8 more
wiley   +1 more source

Revisiting the inhibitory potential of protein kinase inhibitors against NEK7 protein via comprehensive computational investigations. [PDF]

Sci Rep, 2023
Ejaz SA, Aziz M, Zafar Z, Akhtar N, Ogaly HA.   +4 more
europepmc   +1 more source